Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lithium carbonate
Drug ID BADD_D01303
Description Lithium has been used to treat manic episodes since the 19th century[A176642]. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label].
Indications and Usage Lithium is used as a mood stabilizer, and is indicated for the treatment of manic episodes and maintenance of bipolar disorder[FDA Label].
Marketing Status approved
ATC Code Not Available
DrugBank ID DB14509
KEGG ID D00801
MeSH ID D016651
PubChem ID 11125
TTD Drug ID D04UUH
NDC Product Code 31722-546; 62332-148; 62756-430; 63187-304; 64980-205; 68462-221; 70518-0608; 70518-2312; 70518-2345; 70518-3565; 72789-171; 72789-172; 31722-544; 62332-014; 68071-2714; 0054-8531; 46708-303; 55154-4920; 63629-1916; 0378-1450; 70518-0668; 70518-3681; 0054-4527; 62332-013; 68462-220; 68462-222; 68462-223; 70518-0437; 70518-2699; 68084-655; 70518-1434; 0054-2531; 71335-0120; 0054-8528; 0615-8302; 50090-3917; 58118-0545; 0054-8526; 51079-142; 63629-1917; 68462-224; 71610-557; 72789-173; 39345-5104; 46708-305; 0378-1300; 64980-278; 70518-1753; 70518-2086; 0054-2526; 31722-545; 50090-1470; 62332-015; 62559-280; 0054-0020; 68428-481; 0054-2527; 72789-174; 82388-001; 46708-148; 50090-6052; 64117-256; 0054-0021; 68084-640; 70518-0904; 70518-1481; 0054-8527; 66039-947; 73309-248; 23155-763; 42291-496; 43063-901; 46708-304; 51079-180
UNII 2BMD2GNA4V
Synonyms Lithium Carbonate | Carbonate, Lithium | Dilithium Carbonate | Carbonate, Dilithium | Lithane | Lithium Bicarbonate | Bicarbonate, Lithium | Lithobid | Lithonate | CP-15,467-61 | CP 15,467 61 | CP15,46761 | Micalith | NSC-16895 | NSC 16895 | NSC16895 | Priadel | Quilinorm-retard | Quilinorm retard | Quilinormretard | Eskalith | Lithotabs
Chemical Information
Molecular Formula CLi2O3
CAS Registry Number 554-13-2
SMILES [Li+].[Li+].C(=O)([O-])[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sinus node dysfunction02.03.03.017--
Acute motor-sensory axonal neuropathy17.09.01.002; 11.07.01.014; 10.04.10.0110.000535%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000535%
Anal incontinence17.05.01.021; 07.01.06.029--
Acanthosis23.01.04.003--Not Available
Grandiosity19.05.01.0190.000803%Not Available
Tangentiality19.10.03.0110.000535%Not Available
Cardiomyopathy acute02.04.01.0080.000535%Not Available
Renal oncocytoma20.01.04.019; 16.27.01.0080.001071%Not Available
Self esteem inflated19.05.02.0030.000535%Not Available
Sopor19.02.04.002; 17.02.04.0210.000535%Not Available
Stress cardiomyopathy02.04.01.012; 24.04.04.0260.000535%Not Available
Clear cell renal cell carcinoma20.01.04.008; 16.08.02.0040.001071%Not Available
End stage renal disease20.01.03.0190.003748%Not Available
Acquired cystic kidney disease16.27.01.009; 20.01.06.0150.001071%Not Available
Idiopathic intracranial hypertension17.07.02.011--Not Available
Normocytic anaemia01.03.02.0220.000535%Not Available
Oncocytoma16.02.02.0160.001338%Not Available
Therapeutic response prolonged08.06.01.0610.000535%Not Available
Therapy non-responder08.06.01.0630.001178%Not Available
Treatment noncompliance12.09.02.006; 08.06.01.0670.003801%Not Available
The 11th Page    First    Pre   11    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene